What is claimed is:

1. A compound according to formula (I):



(I)

wherein:

R^1 is R^7, or A-C_{0-4}alkyl, A-C_{2-4}alkenyl, A-C_{2-4}alkynyl, A-C_{3-4}oxoalkenyl, A-C_{3-4}oxoalkynyl, A-C_{1-4}aminoalkyl, A-C_{3-4}aminoalkenyl, A-C_{3-4}aminoalkynyl, optionally substituted by any accessible combination of one or more of R^{10} or R^7;

A is H, C_{3-6}cycloalkyl, Het or Ar;

R^7 is -COR^8, -$COCR'_2R^9$, -$C(S)R^8$, -$S(O)_mOR'$, -$S(O)_mNR'R''$, -PO(OR'), -$PO(OR')_2$, -NO_2, or tetrazolyl;

each R^8 independently is -OR', -NR'R", -$NR'SO_2R'$, -NR'OR', or -$OCR'_2CO(O)R'$;

R^9 is -OR', -CN, -$S(O)_rR'$, -$S(O)_mNR'_2$, -C(O)R', C(O)NR'_2, or -CO_2R';

R^{10} is H, halo, -OR^{11}, -CN, -$NR'R^{11}$, -NO_2, -CF_3, $CF_3S(O)_r$-, -CO_2R', -$CONR'_2$, A-C_{0-6}alkyl-, A-C_{1-6}oxoalkyl-, A-C_{2-6}alkenyl-, A-C_{2-6}alkynyl-, A-C_{0-6}alkyloxy-, A-C_{0-6}alkylamino- or A-C_{0-6}alkyl-$S(O)_r$-;

R^{11} is R', -C(O)R', -C(O)NR'_2, -C(O)OR', -$S(O)_mR'$, or -$S(O)_mNR'_2$;

R^2 is



,



,



,



,



;

W is -$(CHR^g)_a$-U- $(CHR^g)_b$-;

U is absent or CO, CR^g_2, $C(=CR^g_2)$, $S(O)_k$, O, NR^g, CR^gOR^g, $CR^g(OR^k)CR^g_2$, $CR^g_2CR^g(OR^k)$, $C(O)CR^g_2$, $CR^g_2C(O)$, $CONR^i$, NR^iCO, OC(O), C(O)O, C(S)O, OC(S), C(S)NR^g, $NR^gC(S)$, $S(O)_2NR^g$, $NR^gS(O)_2$ N=N, NR^gNR^g, $NR^gCR^g_2$, $CR^g_2NR^g$, CR^g_2O, OCR^g_2, C≡C or CR^g=CR^g;

G is NR^e, S or O;

R^g is H, C_{1-6}alkyl, Het-C_{0-6}alkyl, C_{3-7}cycloalkyl-C_{0-6}alkyl or Ar-C_{0-6}alkyl;

R^k is R^g, -C(O)R^g, or -C(O)OR^f;

R^i is is H, C_{1-6}alkyl, Het-C_{0-6}alkyl, C_{3-7}cycloalkyl-C_{0-6}alkyl, Ar- C_{0-6}alkyl, or C_{1-6}alkyl substituted by one to three groups chosen from halogen, CN, NR^g_2, OR^g, SR^g, CO_2R^g, and $CON(R^g)_2$;

R^f is H, C_{1-6}alkyl or Ar-C_{0-6}alkyl;

R^e is H, C_{1-6}alkyl, Ar-C_{0-6}alkyl, Het-C_{0-6}alkyl, C_{3-7}cycloalkyl-C_{0-6}alkyl, or $(CH_2)_kCO_2R^g$;

R^b and R^c are independently selected from H, C_{1-6}alkyl, Ar-C_{0-6}alkyl, Het-C_{0-6}alkyl, or C_{3-6}cycloalkyl-C_{0-6}alkyl, halogen, CF_3, OR^f, $S(O)_kR^f$, COR^f, NO_2, $N(R^f)_2$, $CO(NR^f)_2$, $CH_2N(R^f)_2$, or R^b and R^c are joined together to form a five or six membered aromatic or non-aromatic carbocyclic or heterocyclic ring, optionally substituted by up to three substituents chosen from halogen, CF_3, C_{1-4}alkyl, OR^f, $S(O)_kR^f$, COR^f, CO_2R^f, OH, NO_2, $N(R^f)_2$, $CO(NR^f)_2$, and $CH_2N(R^f)_2$; or methylenedioxy;

Q^1, Q^2, Q^3 and Q^4 are independently N or C-R^y, provided that no more than one of Q^1, Q^2, Q^3 and Q^4 is N;

R' is H, C_{1-6}alkyl, Ar-C_{0-6}alkyl or C_{3-6}cycloalkyl-C_{0-6}alkyl;

R" is R', -C(O)R' or -C(O)OR';

R'" is H, C_{1-6}alkyl, Ar-C_{0-6}alkyl, Het-C_{0-6}alkyl, or C_{3-6}cycloalkyl-C_{0-6}alkyl, halogen, CF_3, OR^f, $S(O)_kR^f$, COR^f, NO_2, $N(R^f)_2$, $CO(NR^f)_2$, $CH_2N(R^f)_2$;

R^y is H, halo, -OR^g, -SR^g, -CN, -NR^gR^k, -NO_2, -CF_3, $CF_3S(O)_r$-, -CO_2R^g, -COR^g or -$CONR^g_2$, or C_{1-6}alkyl optionally substituted by halo, -OR^g, -SR^g, -CN, -NR^gR", -NO_2, -CF_3, R'$S(O)_r$-, -CO_2R^g, -COR^g or -$CONR^g_2$;

a is 0, 1 or 2;

b is 0, 1 or 2;

k is 0, 1 or 2;

m is 1 or 2;

r is 0, 1 or 2;

s is 0, 1 or 2;

u is 0 or 1; and

v is 0 or 1;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 in which R^2 is



,wherein Q^1, Q^2, and Q^3 are each CR^y, Q^4 is CR^y or N and u is 0.

3. A compound according to claim 2 in which each R' is H, R"is H, C_{1-6}alkyl, -C(O)C_{1-6}alkyl, C(O)OC_{1-6}alkyl, -C(O)C_{0-6}alkyl-Ar, or C(O)OC_{0-6}alkyl-Ar, W is -CH_2-CH_2-, and R^y is H, halo, -OR^g, -SR^g, -CN, -NR^gR^k, -NO_2, -CF_3, $CF_3S(O)_r$-, -CO_2R^g, -COR^g -$CONR^g_2$, or C_{1-6}alkyl.

4. A compound according to claim 1 in which R^2 is



,wherein Q^1, Q^2, and Q^3 are each CH and u is 0.

5. A compound according to claim 4 in which each R' is H, R" is H or C_{1-4}alkyl, v is 0 and W is $-CH_2-CH_2-$.

6. A compound according to claim 1 in which R^2 is



, wherein G is NH and R^b and R^c are each H.

7. A compound according to claim 6 in which W is $-NR^g-(CHR^g)_b-$.

8. A compound according to claim 1 in which R^2 is



, wherein G is NH and R^b and R^c are joined together to form a five or six membered aromatic or non-aromatic carbocyclic or heterocyclic ring, optionally substituted by up to three substituents chosen from halogen, CF_3, C_{1-4}alkyl, OR^f, $S(O)_kR^f$, COR^f, CO_2R^f, OH, NO_2, $N(R^f)_2$, $CO(NR^f)_2$, and $CH_2N(R^f)_2$; or methylenedioxy.

9. A compound according to claim 8 in which R^b and R^c are joined together to form a six membered aromatic carbocyclic ring.

10. A compound according to claim 9 in which W is $-CH_2-CH_2-$.

11. A compound according to claim 8 in which R^b and R^c are joined together to form a six membered aromatic heterocyclic ring.

12. A compound according to claim 11 in which W is $-CH_2-CH_2-$.

13. A compound according to claim 1 in which R^2 is



, wherein each R' is H, R" is H or C_{1-4}alkyl, R^g is H or C_{1-4}alkyl and s is 0, 1 or 2.

14. A compound according to claim 13 in which W is $-CH_2-CH_2-$.

15. A compound according to claim 1 in which R^1 is H, C_{1-6}alkyl, Ar-C_{0-6}alkyl, Het-C_{0-6}alkyl, C_{3-6}cycloalkyl-C_{0-6}alkyl, $-CH_2CF_3$, $-(CH_2)_{1-2}C(O)OR'$, or $-(CH_2)_2OR'$, in which R' is H or C_{1-4}alkyl.

16. A compound according to claim 15 in which R^1 is H, C_{1-4}alkyl, Ph-C_{0-4}alkyl, $-CH_2CF_3$, $-(CH_2)_{1-2}C(O)OR'$, or $-(CH_2)_2OR'$, in which R' is H or C_{1-4}alkyl.

17. A compound according to claim 16 in which R^1 is $-CH_2CF_3$.

18. A compound according to claim 1 which is:

(±)-8-[3-(2-pyridylamino)-1-propyloxy]-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-8-[3-(4-amino-2-pyridylamino)-1-propyloxy]-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-8-[3-(4-methoxy-2-pyridylamino)-1-propyloxy]-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-8-[3-(2-pyridylamino)-1-propyloxy]-2-methyl-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-8-[3-(2-imidazolylamino)-1-propyloxy]-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-8-[3-[2-(1,4,5,6-tetrahydropyrimidinyl)amino]-1-propyloxy]-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-8-[3-(6-amino-2-pyridylamino)-1-propyloxy]-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-8-[2-(2-benzimidazolyl)ethoxy]-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-8-[2-(4-aza-2-benzimidazolyl)ethoxy]-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-8-[2-[6-(methylamino)pyridin-2-yl]-1-ethoxy]-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-8-[2-(benzimidazol-2-yl)-1-ethoxy]-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-8-[3-(4-aminopyridin-2-ylamino)-1-propyloxy]-2-methyl-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-3-oxo-8-[3-(pyrimidin-2-ylamino)-1-propyloxy]-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(R)-8-[3-(4-aminopyridin-2-ylamino)-1-propyloxy]-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-3-oxo-8-[3-[(1,4,5,6-tetrahydropyrimidin-2-yl)amino]-1-propyloxy]-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(S)-8-[3-(4-aminopyridin-2-ylamino)-1-propyloxy]-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-3-oxo-8-[3-[N-(pyridin-2-yl)-N-(*tert*-butoxycarbonyl)amino]-1-propyloxy]-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-8-[3-[N-(1-oxopyridin-2-yl)-N-(*tert*-butoxycarbonyl)amino]-1-propyloxy]-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-3-oxo-8-[3-[N-(pyridin-2-yl)-N-(*tert*-butoxycarbonyl)amino]-1-propyloxy]-2-(4-trifluoromethylbenzyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-3-oxo-8-[3-(pyridin-2-ylamino)-1-propyloxy]-2-(4-trifluoromethylbenzyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-2-methyl-3-oxo-8-[3-[N-(pyridin-2-yl)-N-(methyl)amino)]-1-propyloxy]-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-2-benzyl-3-oxo-8-[3-(pyridin-2-ylamino)-1-propyloxy]-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-2-(carboxymethyl)-3-oxo-8-[3-(pyridin-2-ylamino)-1-propyloxy]-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-2-(4-aminobenzyl)-3-oxo-8-[3-(pyridin-2-ylamino)-1-propyloxy]-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-3-oxo-8-[3-[N-(pyridin-2-yl)-N-(benzoyl)amino]-1-propyloxy]-2-(4-trifluoromethylbenzyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-8-[3-(2-imidazolin-2-ylamino)-1-propyloxy]-2-methyl-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-3-oxo-8-[3-(pyridin-2-ylamino)-1-propyloxy]-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-8-[2-(2-aminothiazol-4-yl)-1-ethoxy]-2-methyl-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-8-[3-(4,6-dimethylpyridin-2-ylamino)-1-propyloxy]-2-methyl-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-8-[3-(4,5,6,7-tetrahydro-1H-1,3-diazepin-2-ylamino)-1-propyloxy]-2-methyl-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-3-oxo-8-[3-[N-(pyridin-2-yl)-N-(*tert*-butylacetyl)amino]-1-propyloxy]-2-(4-trifluoromethylbenzyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-3-oxo-8-[3-[N-(pyridin-2-yl)-N-(isobutoxycarbonyl)amino]-1-propyloxy]-2-(4-trifluoromethylbenzyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(S)-3-oxo-8-[3-(pyridin-2-ylamino)-1-propyloxy]-2-(4-trifluoromethylbenzyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-3-oxo-8-[3-(4-methylpyridin-2-ylamino)-1-propyloxy]-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(±)-3-oxo-8-[3-[N-(pyridin-2-yl)-N-(methyl)amino)]-1-propyloxy]-2-[4-(trifluoromethyl)benzyl]-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(S)-3-oxo-8-[3-(pyridin-2-ylamino)-1-propyloxy]-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(R)-3-oxo-8-[3-(pyridin-2-ylamino)-1-propyloxy]-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(S)-8-[3-(4-methylpyridin-2-ylamino)-1-propyloxy]-3-oxo-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(S)-3-oxo-8-[3-(1,4,5,6-tetrahydropyrimid-2-ylamino)-1-propyloxy]-2-[4-(trifluoromethyl)benzyl]-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(S)-3-oxo-2-(2-phenylethyl)-8-[3-(pyridin-2-ylamino)-1-propyloxy]-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(S)-8-[2-[6-(methylamino)pyridin-2-yl]-1-ethoxy]-3-oxo-2-(2-phenylethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

(S)-8-[2-[6-(methylamino)pyridin-2-yl]-1-ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid; or

(S)-8-[2-[6-(methylamino)pyridin-2-yl]-1-ethoxy]-3-oxo-2-[4-(trifluoromethyl)benzyl]-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid;

or a pharmaceutically acceptable salt thereof.

19. A compound according to claim 1 which is (S)-3-oxo-8-[3-(pyridin-2-ylamino)-1-propyloxy]-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid or a pharmaceutically acceptable salt thereof.

20. A compound according to claim 1 which is (S)-8-[2-[6-(methylamino)pyridin-2-yl]-1-ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid or a pharmaceutically acceptable salt thereof.

21. A compound according to claim 1 which is(S)-8-[3-(4-methylpyridin-2-ylamino)-1-propyloxy]-3-oxo-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acidor a pharmaceutically acceptable salt thereof.

22. A pharmaceutical composition which comprises a compound according to claim 1 and a pharmaceutically acceptable carrier.

23. A pharmaceutical composition which comprises a compound according to claim 1, an antineoplastic agent and a pharmaceutically acceptable carrier.

24. The pharmaceutical composition according to claim 23 wherein the antineoplastic agent is topotecan.

25. The pharmaceutical composition according to claim 23 wherein the antineoplastic agent is cisplatin.

26. A pharmaceutical composition which comprises a compound according to claim 1, an inhibitor of bone resorption and a pharmaceutically acceptable carrier.

27. A method of treating a disease state in which antagonism of the $\alpha_v\beta_3$ receptor is indicated which comprises administering to a subject in need thereof a compound according to claim 1.

28. A method of treating a disease state in which antagonism of the $\alpha_v\beta_5$ receptor is indicated which comprises administering to a subject in need thereof a compound according to claim 1.

29. A method of treating osteoporosis which comprises administering to a subject in need thereof a compound according to claim 1.

30. A method for inhibiting angiogenesis which comprises administering to a subject in need thereof a compound according to claim 1.

31. A method for inhibiting tumor growth or tumor metastasis which comprises administering to a subject in need thereof a compound according to claim 1.

32. A method of treating atherosclerosis or restenosis which comprises administering to a subject in need thereof a compound according to claim 1.

33. A method of treating inflammation which comprises administering to a subject in need thereof a compound according to claim 1.

34. A method of inhibiting tumor growth which comprises administering stepwise or in physical combination a compound according to claim 1 and an antineoplastic agent.

35. The method according to claim 34 wherein the antineoplastic agent is topotecan.

36. The method according to claim 34 wherein the antineoplastic agent is cisplatin.

37. A method of treating osteoporosis or inhibiting bone loss which comprises administering stepwise or in physical combination a compound according to claim 1 and an inhibitor of bone resorption.

38. A compound according to formula (II):



(II)

wherein:

R^1 is R^7, or A-C_{0-4}alkyl, A-C_{2-4}alkenyl, A-C_{2-4}alkynyl, A-C_{3-4}oxoalkenyl, A-C_{3-4}oxoalkynyl, A-C_{1-4}aminoalkyl, A-C_{3-4}aminoalkenyl, A-C_{3-4}aminoalkynyl, optionally substituted by any accessible combination of one or more of R^{10} or R^7;

A is H, C_{3-6}cycloalkyl, Het or Ar;

R^7 is -COR^8, -$COCR'_2R^9$, -$C(S)R^8$, -$S(O)_mOR'$, -$S(O)_mNR'R''$, -$PO(OR')$, -$PO(OR')_2$, -NO_2, or tetrazolyl;

each R^8 independently is -OR', -NR'R'', -$NR'SO_2R'$, -NR'OR', or -$OCR'_2CO(O)R'$;

R^9 is -OR', -CN, -$S(O)_rR'$, -$S(O)_mNR'_2$, -C(O)R', $C(O)NR'_2$, or -CO_2R';

R^{10} is H, halo, -OR^{11}, -CN, -$NR'R^{11}$, -NO_2, -CF_3, $CF_3S(O)_r$-, -CO_2R', -$CONR'_2$, A-C_{0-6}alkyl-, A-C_{1-6}oxoalkyl-, A-C_{2-6}alkenyl-, A-C_{2-6}alkynyl-, A-C_{0-6}alkyloxy-, A-C_{0-6}alkylamino- or A-C_{0-6}alkyl-$S(O)_r$-;

R^{11} is R', -C(O)R', -$C(O)NR'_2$, -C(O)OR', -$S(O)_mR'$, or -$S(O)_mNR'_2$;

R^2 is


,

,

,

,

,

,


,

, or



;

W is $-(CHR^g)_a-U-(CHR^g)_b-$;

U is absent or CO, CR^g_2, $C(=CR^g_2)$, $S(O)_k$, O, NR^g, CR^gOR^g, $CR^g(OR^k)CR^g_2$, $CR^g_2CR^g(OR^k)$, $C(O)CR^g_2$, $CR^g_2C(O)$, $CONR^i$, NR^iCO, OC(O), C(O)O, C(S)O, OC(S), $C(S)NR^g$, $NR^gC(S)$, $S(O)_2NR^g$, $NR^gS(O)_2$ N=N, NR^gNR^g, $NR^gCR^g_2$, $CR^g_2NR^g$, CR^g_2O, OCR^g_2, C≡C or CR^g=CR^g;

G is NR^e, S or O;

R^g is H, C_{1-6}alkyl, Het-C_{0-6}alkyl, C_{3-7}cycloalkyl-C_{0-6}alkyl or Ar-C_{0-6}alkyl;

R^k is R^g, $-C(O)R^g$, or $-C(O)OR^f$;

R^i is is H, C_{1-6}alkyl, Het-C_{0-6}alkyl, C_{3-7}cycloalkyl-C_{0-6}alkyl, Ar- C_{0-6}alkyl, or C_{1-6}alkyl substituted by one to three groups chosen from halogen, CN, NR^g_2, OR^g, SR^g, CO_2R^g, and $CON(R^g)_2$;

R^f is H, C_{1-6}alkyl or Ar-C_{0-6}alkyl;

R^e is H, C_{1-6}alkyl, Ar-C_{0-6}alkyl, Het-C_{0-6}alkyl, C_{3-7}cycloalkyl-C_{0-6}alkyl, or $(CH_2)_kCO_2R^g$;

R^b and R^c are independently selected from H, C_{1-6}alkyl, Ar-C_{0-6}alkyl, Het-C_{0-6}alkyl, or C_{3-6}cycloalkyl-C_{0-6}alkyl, halogen, CF_3, OR^f, $S(O)_kR^f$, COR^f, NO_2, $N(R^f)_2$, $CO(NR^f)_2$, $CH_2N(R^f)_2$, or R^b and R^c are joined together to form a five or six membered aromatic or non-aromatic carbocyclic or heterocyclic ring, optionally substituted by up to three substituents chosen from halogen, CF_3, C_{1-4}alkyl, OR^f, $S(O)_kR^f$, COR^f, CO_2R^f, OH, NO_2, $N(R^f)_2$, $CO(NR^f)_2$, and $CH_2N(R^f)_2$; or methylenedioxy;

Q^1, Q^2, Q^3 and Q^4 are independently N or C-R^y, provided that no more than one of Q^1, Q^2, Q^3 and Q^4 is N;

R' is H, C_{1-6}alkyl, Ar-C_{0-6}alkyl or C_{3-6}cycloalkyl-C_{0-6}alkyl;

R" is R', -C(O)R' or -C(O)OR';

R"' is H, C_{1-6}alkyl, Ar-C_{0-6}alkyl, Het-C_{0-6}alkyl, or C_{3-6}cycloalkyl-C_{0-6}alkyl, halogen, CF_3, OR^f, $S(O)_kR^f$, COR^f, NO_2, $N(R^f)_2$, $CO(NR^f)_2$, $CH_2N(R^f)_2$;

R^y is H, halo, $-OR^g$, $-SR^g$, -CN, $-NR^gR^k$, $-NO_2$, $-CF_3$, $CF_3S(O)_r-$, $-CO_2R^g$, $-COR^g$ or $-CONR^g_2$, or C_{1-6}alkyl optionally substituted by halo, $-OR^g$, $-SR^g$, -CN, $-NR^gR"$, $-NO_2$, $-CF_3$, $R'S(O)_r-$, $-CO_2R^g$, $-COR^g$ or $-CONR^g_2$;

a is 0, 1 or 2;

b is 0, 1 or 2;

k is 0, 1 or 2;

m is 1 or 2;

r is 0, 1 or 2;

s is 0, 1 or 2;

u is 0 or 1; and

v is 0 or 1;

or a pharmaceutically acceptable salt thereof.

39. A compound according to claim 38 which is:

methyl (±)-3-oxo-8-[3-(pyridin-2-ylamino)-1-propyloxy]-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetate; or

ethyl (±)-8-[3-(4-aminopyridin-2-ylamino)-1-propyloxy]-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetate;

or a pharmaceutically acceptable salt thereof.

40. A compound according to formula (III):



(III)

R^1 is R^7, or A-C_{0-4}alkyl, A-C_{2-4}alkenyl, A-C_{2-4}alkynyl, A-C_{3-4}oxoalkenyl, A-C_{3-4}oxoalkynyl, A-C_{1-4}aminoalkyl, A-C_{3-4}aminoalkenyl, A-C_{3-4}aminoalkynyl, optionally substituted by any accessible combination of one or more of R^{10} or R^7;

A is H, C_{3-6}cycloalkyl, Het or Ar;

R^7 is -COR^8, -$COCR'_2R^9$, -$C(S)R^8$, -$S(O)_mOR'$, -$S(O)_mNR'R''$, -PO(OR'), -$PO(OR')_2$, -NO_2, or tetrazolyl;

each R^8 independently is -OR', -NR'R'', -$NR'SO_2R'$, -NR'OR', or -$OCR'_2CO(O)R'$;

R^9 is -OR', -CN, -$S(O)_rR'$, -$S(O)_mNR'_2$, -C(O)R', C(O)NR'_2, or -CO_2R';

R^{10} is H, halo, -OR^{11}, -CN, -$NR'R^{11}$, -NO_2, -CF_3, $CF_3S(O)_r$-, -CO_2R', -$CONR'_2$, A-C_{0-6}alkyl-, A-C_{1-6}oxoalkyl-, A-C_{2-6}alkenyl-, A-C_{2-6}alkynyl-, A-C_{0-6}alkyloxy-, A-C_{0-6}alkylamino- or A-C_{0-6}alkyl-$S(O)_r$-;

R^{11} is R', -C(O)R', -C(O)NR'_2, -C(O)OR', -$S(O)_mR'$, or -$S(O)_mNR'_2$;

W is -$(CHR^g)_a$-U- $(CHR^g)_b$-;

U is absent or CO, CR^g_2, C(=CR^g_2), $S(O)_k$, O, NR^g, CR^gOR^g, $CR^g(OR^k)CR^g_2$, $CR^g_2CR^g(OR^k)$, C(O)CR^g_2, CR^g_2C(O), $CONR^i$, NR^iCO, OC(O), C(O)O, C(S)O, OC(S),

$C(S)NR^g$, $NR^gC(S)$, $S(O)_2NR^g$, $NR^gS(O)_2$ N=N, NR^gNR^g, $NR^gCR^g_2$, $CR^g_2NR^g$, CR^g_2O, OCR^g_2, C≡C or CR^g=CR^g;

R^g is H, C_{1-6}alkyl, Het-C_{0-6}alkyl, C_{3-7}cycloalkyl-C_{0-6}alkyl or Ar-C_{0-6}alkyl;

R^k is R^g, -C(O)R^g, or -C(O)OR^f;

R^i is is H, C_{1-6}alkyl, Het-C_{0-6}alkyl, C_{3-7}cycloalkyl-C_{0-6}alkyl, Ar- C_{0-6}alkyl, or C_{1-6}alkyl substituted by one to three groups chosen from halogen, CN, NR^g_2, OR^g, SR^g, CO_2R^g, and $CON(R^g)_2$;

R^f is H, C_{1-6}alkyl or Ar-C_{0-6}alkyl;

Q^1, Q^2, Q^3 and Q^4 are independently N or C-R^y, provided that no more than one of Q^1, Q^2, Q^3 and Q^4 is N;

R' is H, C_{1-6}alkyl, Ar-C_{0-6}alkyl or C_{3-6}cycloalkyl-C_{0-6}alkyl;

R" is R', -C(O)R' or -C(O)OR';

R^y is H, halo, $-OR^g$, $-SR^g$, -CN, $-NR^gR^k$, $-NO_2$, $-CF_3$, $CF_3S(O)_r$-, $-CO_2R^g$, $-COR^g$ or $-CONR^g_2$, or C_{1-6}alkyl optionally substituted by halo, $-OR^g$, $-SR^g$, -CN, $-NR^gR''$, $-NO_2$, $-CF_3$, R'$S(O)_r$-, $-CO_2R^g$, $-COR^g$ or $-CONR^g_2$;

a is 0, 1 or 2;

b is 0, 1 or 2;

m is 1 or 2; and

r is 0, 1 or 2;

or a pharmaceutically acceptable salt thereof.

41. A process for preparing a compound of the formula (I) as defined in claim 1, which process comprises reacting a compound of formula (IV) with a compound of formula (V):



(IV)

R^2-L^1

(V)

wherein R^1 and R^2 are as defined in formula (I), with any reactive functional groups protected, and L^1 is OH or halo;

and thereafter removing any protecting groups, and optionally forming a pharmaceutically acceptable salt.

42. A process for preparing a compound of the formula (I) as defined in claim 1, which process comprises reacting a compound of formula (IV) with a compound of formula (VI):



(IV)



(VI)

wherein R^1, R', R", W, Q^1, Q^2, Q^3 and Q^4 are as defined in formula (I), with any reactive functional groups protected;

and thereafter removing any protecting groups, and optionally forming a pharmaceutically acceptable salt.

43. A process for preparing a compound of the formula (I) as defined in claim 1, which process comprises reacting a compound of formula (IV) with a compound of formula (VII):



(IV)



(VII)

wherein R^1, R', R", W, Q^1, Q^2, Q^3 and v are as defined in formula (I), with any reactive functional groups protected;

and thereafter removing any protecting groups, and optionally forming a pharmaceutically acceptable salt.

44. A compound according to any one of claims 1 to 21 for use as a medicament.

45. The use of a compound of the formula (I) as defined in claim 1 in the manufacture of a medicament for the treatment of diseases in which antagonism of the $\alpha_v\beta_3$ receptor is indicated.

46. The use of a compound of the formula (I) as defined in claim 1 in the manufacture of a medicament for the treatment of diseases in which antagonism of the $\alpha_v\beta_5$ receptor is indicated.

47. The use of a compound of the formula (I) as defined in claim 1 in the manufacture of a medicament for the treatment of osteoporosis.

48. The use of a compound of the formula (I) as defined in claim 1 in the manufacture of a medicament for the inhibition of angiogenesis.

49. The use of a compound of the formula (I) as defined in claim 1 in the manufacture of a medicament for the inhibition of tumor growth or tumor metastasis.

50. The use of a compound of the formula (I) as defined in claim 1 in the manufacture of a medicament for the treatment of atherosclerosis or restenosis.

51. The use of a compound of the formula (I) as defined in claim 1 in the manufacture of a medicament for the treatment of inflammation.

52. The use of a compound of the formula (I) as defined in claim 1 and an antineoplastic agent in the manufacture of a medicament for the inhibition of tumor growth in physical combination or for stepwise administration.

53. The use according to claim 52 wherein the antineoplastic agent is topotecan.

54. The use according to claim 52 wherein the antineoplastic agent is cisplatin.

55. The use of a compound of the formula (I) as defined in claim 1 and an inhibitor of bone resorption in the manufacture of a medicament for the treatment of osteoporosis in physical combination or for stepwise administration.